CSI Market
Sign In | Register

Zevra Therapeutics Inc (ZVRA) Quarterly Cash Flow Statement

Quarterly · GAAP · USD millions
Access ZVRA Annual Cash Flow →
This page allows investors to follow Zevra Therapeutics Inc's cash flow patterns across multiple reporting periods and assess consistency in cash generation.
View historic periods: Download as CSV:
Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.
Quarterly Report, GAAP in USD millions
ITEM 		(Jun 30 2026)
6 Months 		(Mar 31 2026) (Dec 31 2025) (Sep 30 2025) (Jun 30 2025)
Operating Activities
Income91.36
Depreciation & amortization0.73
Amortization of Other Assets0.63
Extraordinary Item, Gain (Loss), Insurance Assets, Accretion Expense0.00
Impairment of Intangible Assets, Finite-lived43.30
Provision For Loan Losses Expensed0.00
Inventories Decrease /-Increase0.81
Research and Development in Process0.00
Gain (Loss) on Disposition of Intangible Assets0.00
Share-based Compensation6.07
Income (Loss) from Equity Method Investments0.00
Financial Instruments and Foreign Currency Transaction-0.95
Current Portion Of Convertible Notes-
Deferred Offering Costs Writeoff-
Increase Decrease In Operating Lease Rightofuse Asset-
Loss On Sublease And Disposal Of Property And Equipment-
Fair Value Adjustment Of Investments0.22
Income Tax Expense Benefit Noncash Adjustment6.91
Increase Decrease In Discount And Rebate Liabilities-
Fair Value Adjustment Related To Warrant And C V R Liability-0.97
Gain On Sale Of Priority Review Voucher-
Discount And Rebate Liabilities1.15
Fair Value Adjustment Related To Derivative Instrument7.22
Cash Paid To Settle Derivative Instrument And Payoff Premium-9.02
Payment Of Paid In Kind Interest-3.13
Consulting Fees Paid In Common Stock-
Increase Decrease In Operating Lease Right Of Use Asset-
Income taxes0.00
Losses/ -gains on Investments net-7.22
Increase (Decrease) in Accounts and Other Receivables-1.15
Accounts Payable1.79
Accrued Expense0.00
Deferred Revenue and Customer Advances and Deposits0.00
Increase (Decrease) in Prepaid Expense and Other Assets-2.20
Other Working Capital0.76
Other Noncash Expense0.34
Other net1.22
Payments for (Proceeds from) Other Operating Activities-112.33
Discontinued operations0.00
Net Cash flow from Operating Activities23.17
Investing Activities
Capital Expenditures-0.25
Sale of Capital Items48.94
Payments for (Proceeds from) Investments0.00
Short-term Investments Acq.0.00
Real Estate Investments0.00
Proceeds From Sale Of Priority Review Voucher-
Restricted Cash and Investments Increase (Decrease)0.00
Payments for (Proceeds from) Loans0.00
Payments for (Proceeds from) Deposits0.00
Payments for (Proceeds from) Other Investments62.39
Payments for (Proceeds from) Federal Reserve and FHLB0.00
Acquisition Net of Cash Acquired0.00
Interest in Subsidiaries and Affiliates0.00
Sale of businesses0.00
Accounts payable0.00
Payments to Acquire Notes Receivable0.00
Payments for (Proceeds from) Other Investing Activities0.00
Other Net0.00
Discontinued operations0.00
Net Cash Flow from Investing Activities111.07
Financing Activities
Short-term debt Net0.00
Other borrowing transactions0.00
Long-term debt - borrowings-60.09
Long-term debt - repayments0.00
Federal Home Loan Bank and Federal Funds0.00
Issuances / -repurchases of Comm. Stock9.92
Partnership and Parent Transactions0.00
Issuances / -repurchases of Pref. Stock0.00
Deposits, Annuities, Contract Holders Funds0.00
Other financing activities net-1.05
Other net0.00
Proceeds From Underwritten Public Offering Net-
Finance Lease Principal Payments-
Proceeds From Insurance Financing Arrangements-
Proceeds From Employee Stock Purchase Plan-
Payments Of Principal On Insurance Financing Arrangements-
Payments of Dividends, Preferred Stock and Preference Stock0.00
Dividends paid0.00
Net Cash Flow from Financing Activities-51.22
Effect of exchange rate on cash flow0.00
Discontinued operations0.00
Free Cash Flow71.86
Total Cash Flow82.92
4 historic quarters locked

Sign in to unlock the full Zevra Therapeutics Inc cash flow history.

Sign In Create Free Account

About Zevra Therapeutics Inc Quarterly Cash Flow Statement

What this statement shows

This page presents issuer-reported cash flow data, including operating, investing, financing, net, and free cash flow, as disclosed in SEC 10-Q filings and normalized by CSIMarket.

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - normalization in the CSIMarket.com database.
  • Accession: 0001434647-26-000068

Figures are derived from filed reports and may be restated. Historical data is subject to revision.